Novo Nordisk’s $8.5B Bid Challenges Pfizer’s Obesity Ambitions
The obesity drug market heats up as Novo Nordisk launches a rival $8.5 billion bid for Metsera, directly challenging Pfizer’s existing offer. This bidding war signals intensifying competition for dominance in the lucrative weight-loss treatment space with significant implications for both companies’